AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows:
- oncology (36.8%);
- respiratory diseases (22.9%);
- cardiovascular, renal and metabolic diseases (18.6%);
- other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases.
Net sales are distributed geographically as follows: the United Kingdom (2%), Continental Europe (16.5%), Americas (38.3%) and Africa/Asia/Australia (43.2%).
Number of employees : 70 600 people.
2018 2019 Delta GBP (in Million) % GBP (in Million) % Oncology 4,521 27.3% 6,794 35.5% +50.28% Cardiovascular, Renal & Metabolism 5,032 30.4% 5,413 28.3% +7.57% Respiratory 3,683 22.2% 4,226 22.1% +14.74% Other Diseases 2,550 15.4% 2,039 10.7% -20.04% Externalisation Revenue 780.71 4.7% 641.98 3.4% -17.77%
2019 GBP (in Million) % United States 6,308 33% China 3,815 20% Japan 1,977 10.3% United Kingdom 1,428 7.5% Other Asia, Africa and Australasia 1,112 5.8% Other Continental Europe 1,012 5.3% Sweden 653.74 3.4% Other Americas 638.06 3.3% Germany 551.84 2.9% France 453.07 2.4%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,312,307,462
1,256,516,741
95.7% 0
0.0% 95.7%
Shareholders AstraZeneca PLC (GB0009895292) AstraZeneca PLC (US)
Name Equities % Investor AB (Investment Company) 51,587,810
3.93% BlackRock Investment Management (UK) Ltd. 42,170,900
3.21% Capital Research & Management Co. (World Investors) 41,526,368
3.16% The Vanguard Group, Inc. 39,268,235
2.99% Wellington Management Co. LLP 38,725,550
2.95% Norges Bank Investment Management 31,032,000
2.36% BlackRock Fund Advisors 24,835,517
1.89% Legal & General Investment Management Ltd. 24,626,000
1.88% Fidelity Management & Research Co. LLC 17,532,022
1.34% BlackRock Advisors (UK) Ltd. 17,103,169
1.30%
Name Equities % Investor AB (Investment Company) 190,171,620
7.25% Wellington Management Co. LLP 54,544,517
2.08% PRIMECAP Management Co. 51,498,061
1.96% Fidelity Management & Research Co. LLC 42,939,426
1.64% Jennison Associates LLC 31,035,458
1.18% Capital Research & Management Co. (International Investors) 29,249,466
1.11% Fisher Asset Management LLC 17,342,680
0.66% Capital Research & Management Co. 14,965,800
0.57% Dodge & Cox 14,821,346
0.56% T. Rowe Price Associates, Inc. (Investment Management) 13,610,125
0.52%
Name Equities % Valuation
AstraZeneca Pharma India Limited (506820) 18,750,000 75.0% 1,088,667,750 USD Viela Bio, Inc. (VIE) 14,650,334 26.8% 467,492,158 USD ADC Therapeutics SA (ADCT) 3,811,215 4.97% 109,343,758 USD Innate Pharma (IPH) 7,485,500 9.48% 29,663,689 USD Circassia Group Plc (CIR) 71,081,217 17.9% 19,897,765 USD PhaseBio Pharmaceuticals, Inc. (PHAS) 3,004,554 10.2% 8,202,432 USD Entasis Therapeutics Holdings Inc. (ETTX) 2,164,855 6.10% 3,485,417 USD
-
- Main Market
- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, OMX Stockholm 30, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
- Bloomberg Code :
AZN:LN
- Reuters Code :
AZN.L
- Datastream Code :
AZN
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire
Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site :
http://www.astrazeneca.com
Moderna files for U.S. vaccine authorization, will seek EU nod
Sector Pharmaceuticals - NEC
Connections : AstraZeneca PLC
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
